Embryonic stem cell drugs may enter clinical research next year
-
Last Update: 2020-07-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, Geron, a research company for embryonic stem cells, announced at the annual meeting of the American Association of Neuroscience that its research drug GRNOPC1 is expected to enter clinical research in 2008GRNOPC1 is a technology drug for the treatment of spinal cord injury based on human embryonic stem cellsIf approved by the FDA, it would be the first new drug to enter the clinic on a basis based on embryonic stem cellsIt is reported that GRNOPC1 in the spinal cord injury mouse model only need to be injected once, that is, within 9 months showed significant neurorepair effect, and in contrast to other stem cell treatments, injection of GRNOPC1 into the spinal cord injury did not exacerbate neuropathic painThe researchers note that the experiment at least confirms that embryonic stem cells are much safer and more effective in spinal cord therapy applications than stem cell-based treatments, and that grnoPC1 will progress faster once it enters the clinic because of the large number of patients with spinal cord injuries and the absence of ready-made treatment drugs and methods(Wang Hai)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
